Anastrozole

DEA Class; Rx

Common Brand Names; Arimidex

• Antineoplastics, Aromatase Inhibitor

Hypersensitivity

May cause fetal harm or loss; use is contraindicated in women who are or may become pregnant

• Hot flashes (12-36%)
• Vasodilation (25-36%)
• Fatigue (19%)
• Mood disturbances (19%)
• Nausea and vomiting (19%)
• Weakness (16-19%)
• Arthritis (17%)
• Pain (17%)
• Arthralgia (2-15%)
• Pharyngitis (14%)
• Depression (13%)
• Hypertension (2-13%)
• Bone pain (11%)
• Increased cough (11%)
• Osteoporosis (11%)
• Rash (8-11%)
• 1-10%
• Accidental injury (10%)
• Back pain (10%)
• Fracture (10%)
• Headache (10%)
• Insomnia (10%)
• Peripheral edema (10%)
• Dyspnea (8-10%)
• Abdominal pain (9%)

Increased incidence of ischemic cardiovascular events in women with preexisting ischemic heart disease; use only if benefits greatly outweigh risks

Decreases lumbar spine and total hip bone mineral density; increased risk of fractures and osteoporosis; concurrent use with bisphosphonates may be useful in patients at risk for fractures; follow available guidelines for bone mineral density management in postmenopausal women; patients with preexisting osteopenia are at higher risk for developing osteoporosis

Elevated serum cholesterol reported; monitor closely; use with caution in patients with hyperlipidemias; monitor and manage cholesterol levels with current guidelines for patients with LDL elevations

Affords no clinical benefit to premenopausal women with breast cancer

Increased risk of ischemic cardiovascular events in patients with pre-existing ischemic cardiac disease

Based on findings from animal studies and mechanism of action, therapy may cause fetal harm when administered to pregnant woman; there are no studies on use in pregnant women

There are no data on presence of drug or metabolites in human milk, or effects on breast-fed child or on milk production

Anastrozole

tablet

• 1mg